Voordat u verdergaat naar Farmacotherapie

We gebruiken cookies voor het volgende:
Nieuwe features ontwikkelen
Evalueren en optimaliseren van features
Gepersonaliseerde content laten zien
Ervaringen meten
Farmacotherapie.org maakt op haar websites gebruik van cookies. Een cookie is een klein bestandje dat met een pagina van een website wordt meegestuurd en door uw browser (tijdelijk) op de harde schrijf van uw computer of mobiele apparatuur wordt opgeslagen.
Heeft u vragen over ons cookiebeleid? Neem dan contact op met onze helpdesk
Algemene voorwaarden Privacyverklaring Helpdesk

Zoeken
Mijn publicaties
Log in met Medi-Access om mijn publicaties te configureren
Wachtwoord vergeten?
Nog geen account? Nu aanmelden
Notificaties
Log in met Medi-Access om notificaties te ontvangen
Wachtwoord vergeten?
Nog geen account? Nu aanmelden
Account
Inloggen met Medi-Access
Heeft u nog geen account? Nu aanmelden
Wachtwoord vergeten?
Specialismen
Specialismen
Terug
Algemeen
Algemeen
Terug
Bekijk alles binnen AlgemeenBeeldvormingBijwerkingenPijnSeksualiteitVoeding
Cardiologie
Cardiologie
Terug
Bekijk alles binnen CardiologieCholesterol
Dermatologie
Dermatologie
Terug
Bekijk alles binnen DermatologieEczeemPsoriasis
Endocrinologie
Endocrinologie
Terug
Bekijk alles binnen EndocrinologieDiabetes mellitus
GGZ en gedrag
GGZ en gedrag
Terug
Bekijk alles binnen GGZ en gedragCognitie
Hematologie
Hematologie
Terug
Bekijk alles binnen HematologieAntistollingEmbolieITPTrombose
Immunologie
Immunologie
Terug
Bekijk alles binnen ImmunologieAllergiehivImmuuntherapieInfectieziektenRSV
Interne geneeskunde
Interne geneeskunde
KNO
KNO
MDL
MDL
Terug
Bekijk alles binnen MDLColitis ulcerosaDarmIBDLeverZiekte van Crohn
Nefrologie
Nefrologie
Terug
Bekijk alles binnen NefrologieNier
Neurologie
Neurologie
Terug
Bekijk alles binnen NeurologieHersenenMultiple ScleroseZenuw
Oncologie
Oncologie
Terug
Bekijk alles binnen OncologieBorstkankerLeukemieMelanoomTumor
Oogheelkunde
Oogheelkunde
Terug
Bekijk alles binnen OogheelkundeMaculadegeneratieRetinopathie
Orthopedie
Orthopedie
Pathologie
Pathologie
Pulmonologie
Pulmonologie
Terug
Bekijk alles binnen PulmonologieAstmaCOPDLongRinitis
Reumatologie
Reumatologie
Terug
Bekijk alles binnen ReumatologieArtritisArtritis psoriaticaAxiale SpAGewrichtsklachtenLupus nefritisReumatoïde ArtritisSLE
Urologie
Urologie
Terug
Bekijk alles binnen UrologieBlaassyndroomProstaat
Onderwerpen
Publicaties
Videospecials
Auteurs
Systemische lupus erythematosus (SLE)
Literatuuropgave

Literatuuropgave

  1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
  2. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86.
  3. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12.
  4. Arnaud L, Fagot JP, Mathian A, et al. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13(11):1082-9.
  5. Brinks R, Hoyer A, Weber S, et al. Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002. Lupus Sci Med. 2016;3(1):e000181.
  6. Hermansen ML, Lindhardsen J, Torp-Pedersen C, et al. Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. J Rheumatol. 2016;43(7):1335-9.
  7. Ingvarsson RF, Bengtsson AA, Jonsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus. 2016;25(7):772-80.
  8. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016;75(1):136-41.
  9. Gergianaki I, Fanouriakis A, Repa A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76(12):1992-2000.
  10. Otsa K, Talli S, Harding P, et al. Prevalence and incidence of systemic lupus erythematosus in the adult population of Estonia. Lupus. 2017;26(10):1115-20.
  11. Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore). 2011;90(5):350-8.
  12. Riveros Frutos A, Casas I, Rua-Figueroa I, et al. Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort. Lupus. 2017;26(7):698-706.
  13. Goncalves MJ, Sousa S, Ines LS, et al. The weaker sex: Characterization of gender disparities in a nationwide lupus register (Reuma.pt/SLE). Joint Bone Spine. 2015;82(5):378-80.
  14. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35(3):311-8.
  15. Arnaud L, Mertz P, Gavand PE, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78(4):504-8.
  16. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990;33(5):634-43.
  17. Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-30.
  18. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16040.
  19. Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Autoimmun Rev. 2017;16(11):1160-73.
  20. Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107(21):9813-8.
  21. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.
  22. Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270.
  23. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun. 2013;41:25-33.
  24. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-5.
  25. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-62.
  26. Seth A, Craft J. Spatial and functional heterogeneity of follicular helper T cells in autoimmunity. Curr Opin Immunol. 2019;61:1-9.
  27. Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum. 1995;38(4):506-16.
  28. Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902-14.
  29. Crispin JC, Tsokos GC. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol. 2010;22(5):499-503.
  30. Li W, Deng C, Yang H, et al. The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. Front Immunol. 2019;10:159.
  31. Bultink IE, Teerlink T, Heijst JA, et al. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(9):1362-5.
  32. Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014;41(4):680-7.
  33. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-7.
  34. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med. 2005;257(6):485-95.
  35. Bultink IEM. Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. Calcif Tissue Int. 2018;102(5):575-91.
  36. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum. 1996;25(5):318-36.
  37. El Hadiyen F, Tsang-A-Sjoe MWP, Lissenberg-Witte BI, Voskuyl AE, Bultink IEM. Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81.
  38. Bultink IE, Hamann D, Seelen MA, et al. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res Ther. 2006;8(6):R183.
  39. Wadstrom H, Arkema EV, Sjowall C, et al. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56(4):613-9.
  40. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5.
  41. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630-40.
  42. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447-58.
  43. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-8.
  44. Chessa E, Piga M, Floris A, et al. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford). 2020;59(12):3622-32.
  45. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143-51.
  46. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-78.
  47. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-31.
  48. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-9.
  49. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67.
  50. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-85.
  51. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45.
  52. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005;32(8):1467-72.
  53. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-22.
  54. Tsang-A-Sjoe MWP, Bultink IE, Heslinga M, et al. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(1):121-8.
  55. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615-21.
  56. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74.
  57. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-82.
  58. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82.
  59. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1).
  60. Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2022;9(1).
  61. Tsang-A-Sjoe MWP, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015;16(18):2793-806.
  62. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8.
  63. Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;27(9):2142-5.
  64. Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244-9.
  65. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-60.
  66. Kim JW, Kim YY, Lee H, et al. Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. J Rheumatol. 2017;44(11):1674-9.
  67. Costedoat-Chalumeau N, Isenberg D, Petri M. Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. Ann Rheum Dis. 2020;79(8):e90.
  68. Marmor MF, Kellner U, Lai TY, et al. American Academy of O. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-94.
  69. Nederlandse Vereniging voor Reumatologie (NVR). https://www.nvr.nl/wp-content/uploads/2018/12/StandpuntHCQretinopathierevisiehr2018nov.pdf.
  70. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-82.
  71. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-32.
  72. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. Arthritis Care Res (Hoboken). 2018;70(4):582-91.
  73. Blumenfeld Z, Mischari O, Schultz N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum. 2011;41(3):346-52.
  74. Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706-13.
  75. Yee CS, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836-43.
  76. Chen HL, Shen LJ, Hsu PN, et al. Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study. J Rheumatol. 2018;45(1):83-9.
  77. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50.
  78. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-31.
  79. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-4.
  80. Tamirou F, Husson SN, Gruson D, et al. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Mullerian Hormone. Arthritis Rheumatol. 2017;69(6):1267-71.
  81. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-40.
  82. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-13.
  83. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-95.
  84. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-28.
  85. Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
  86. Nederlandse Vereniging voor Reumatologie (NVR). Standpunt van de Nederlandse Vereniging voor Reumatologie inzake de toepassing van belimumab bij volwassen patiënten met Systemische Lupus Erythematosus (SLE). https://www.nvr.nl/wp-content/uploads/2022/4/STANDPUNT-Belimumab-NVR-rev....
  87. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2(5):968-75.
  88. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22(7):1933-42.
  89. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12.
  90. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44.
  91. Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-40.
  92. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26.
  93. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-80.
  94. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30.
  95. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343-9.
  96. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-8.
  97. Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017;69(5):1016-27.
  98. Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(7):1125-34.
  99. Strand V, Berry P, Lin X, et al. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken). 2019;71(6):829-38.
  100. Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019;78(3):372-9.
  101. Parodis I, Gomez A, Frodlund M, et al. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opin Biol Ther. 2018;18(8):911-20.
  102. Parodis I, Gomez A, Emamikia S, et al. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(7):1006-7.
  103. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. The Lancet Rheumatology. 2019;1(4):e208-e19.
  104. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211-21.
  105. Ryden-Aulin M, Boumpas D, Bultink I, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3(1):e000163.
  106. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-66.
  107. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75-81.
  108. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64.
  109. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24(7):2157-60.
  110. NVALT. Richtlijn TBC-screening immuunsuppressieva. 2019. https://richtlijnendatabase.nl/richtlijn/tbc-screening_immuunsuppressiva/startpagina.html.
  111. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39(8):1632-40.
  112. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81.
  113. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22.
  114. van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10(6):341-52.
  115. Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-42.
  116. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31.
  117. Houssiau FA, Thanou A, Mazur M, et al. IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020;79(3):347-55.
  118. Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-17.
  119. He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-9.
  120. Mok CC. Treat-to-target in systemic lupus erythematosus: are we there yet? Expert Rev Clin Pharmacol. 2016;9(5):675-80.
  121. Mucke J, Kuss O, Brinks R, et al. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial. Lupus Sci Med. 2021;8(1).
  122. Luis MSF, Bultink IEM, da Silva JAP, et al. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology (Oxford). 2021;60(11):5134-41.
  123. NVR. Richtlijn Medicatiegebruik bij inflammatoire reumatische aandoeningen rondom de zwangerschap. 2021. https://nvr.nl/Richtlijn-Zwangerschap_31jan2022_def.pdf.
  124. Mendel A, Bernatsky SB, Hanly JG, et al. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019;78(7):1010-2.
  125. Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.
Opslaan
Opslaan
Reumatologie

Systemische lupus erythematosus (SLE)

Downloads: 2
Lancering: 29-09-2022
Laatst bijgewerkt: 16-10-2023
dr. I.E.M. Bultinkdr. M.W.P. Tsang-A-Sjoe

Deze Farmacotherapie-Online publicatie gaat in op de nieuwste behandelingsmogelijkheden voor systemische lupus erythematosus (SLE).

Leerdoelen

U bent op de hoogte van de nieuwste EULAR/ACR classificatiecriteria voor SLE
U weet welke behandelmogelijkheden u in kunt zetten bij uw patiënten met SLE
U kent de treat-to-target aanpak en weet hoe u deze kunt vormgeven
U bent op de hoogte van nieuwe definities voor remissie en lage ziekteactiviteit bij SLE

Beschikbaar materiaal

Download presentatie
Log in met Medi-Access om de presentatie te downloaden

Systemische lupus erythematosus (SLE) is een chronische auto-immuunziekte waarbij meerdere orgaansystemen betrokken zijn. Hoewel de overleving van SLE-patiënten is verbeterd, is de ziektelast hoog en is het voorkomen van exacerbaties en orgaanschade een grote uitdaging, evenals het tijdig opsporen en behandelen van comorbiditeiten.

In deze geactualiseerde Farmacotherapie-Online publicatie bespreken reumatologen dr. Irene Bultink en dr. Michel Tsang-A-Sjoe het ziektebeeld SLE en de therapeutische mogelijkheden. De nadruk ligt op de nieuwste behandelingsmogelijkheden. Daarbij dienen recente Nederlandse en Europese richtlijnen als leidraad. De publicatie sluit af met nieuwe, relevante casuïstiek.

Deze publicatie is een actualisatie van het artikel ‘Systemische lupus erythematosus (SLE)’ door Dr. I.E.M. Bultink, reumatoloog en Prof.dr. R.F. van Vollenhoven.

Auteurs

dr. I.E.M. Bultink
dr. M.W.P. Tsang-A-Sjoe

Bekijk meer van

ReumatologieArtritisArtritis psoriaticaAxiale SpAGewrichtsklachten...
Reumatologie

Systemische lupus erythematosus (SLE)

Downloads: 2
Lancering: 29-09-2022
Laatst bijgewerkt: 16-10-2023
dr. I.E.M. Bultinkdr. M.W.P. Tsang-A-Sjoe

Deze Farmacotherapie-Online publicatie gaat in op de nieuwste behandelingsmogelijkheden voor systemische lupus erythematosus (SLE).

Log in met Medi-Access om de inhoud te bekijken

Heeft u nog geen account? Nu aanmelden
Wachtwoord vergeten?
Mede mogelijk gemaakt door
Farmacotherapie
PublicatiesVideospecialsSpecialismenOnderwerpenAuteursSponsoren
Specialismen
Specialismen
AlgemeenCardiologieDermatologieEndocrinologieGGZ en gedragHematologieImmunologieInterne geneeskundeKNOMDLNefrologieNeurologieOncologieOogheelkundeOrthopediePathologiePulmonologieReumatologieUrologie
Geef ons feedback
Tip de redactie
Helpdesk
Algemene voorwaardenPrivacyverklaringCookiesContactOverHelpdesk